Reducing low-density lipoprotein cholesterol (LDL-C) with statin therapy represents the cornerstone of dyslipidaemia management in patients with cardiovascular disease, as reflected in current treatment guidelines. Yet even among statin-treated patients who achieve LDL-C targets (< 2.59 mmol/L [100 mg/dL]), the residual risk of further cardiovascular events remains unacceptably high. Although clinical studies indicate that intensive LDL-C lowering may provide some additional benefit, this does not suppress the excess cardiovascular risk sufficiently. This European Expert Panel therefore recognises that there is an unmet clinical need in the management of these patients. Additional intervention to modify other clinically important risk factors should be viewed as a priority.
A reduced level of high-density lipoprotein cholesterol (HDL-C) < 1.03 mmol/L (40 mg/dL) in men and < 1.29 mmol/L (50 mg/dL) in women is an important independent predictive factor for coronary heart disease. HDL-C levels are also predictive of cardiovascular risk in statin-treated patients, irrespective of their LDL-C levels. Therefore, HDL-C represents a logical therapeutic target for reducing cardiovascular risk further in statin-treated patients, including those who achieve LDL-C targets. Given that low HDL-C is common among dyslipidaemic patients with cardiovascular disease, a therapeutic strategy aimed at effectively raising HDL-C, while at the same time lowering LDL-C to target levels, would be expected to offer clinical benefit beyond that achieved through LDL-C reduction alone. Although both nicotinic acid and fibrates raise HDL-C, nicotinic acid has greater potency. Studies show that combination therapy with prolonged-release (PR) nicotinic acid and a statin has an acceptable tolerability profile, normalises an atherogenic lipoprotein profile, and is able to induce regression of atherosclerosis and reduce coronary risk in patients with established cardiovascular disease and suboptimal HDL-C levels.
In conclusion, this European Expert Panel recommends that combination therapy with a statin and an HDL-C raising agent, such as PR nicotinic acid, should be considered in these patients, who remain at high residual risk despite achieving target LDL-C levels with statin monotherapy. Ongoing studies are essential to confirm the clinical outcome benefits of this approach.
References
1.
1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA2001;285:2486–97.
2.
2. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. http://www.athero.org. [Integrating the guidelines of the International Task Force for Prevention of Coronary Heart Disease, http://www.chd-taskforce.de/guidelines/toc.htm and the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)]. Accessed 25 Feb 2006.
3.
3. De Backer G, Ambrosioni E, Borch-Johnsen Ket al.Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J2003;24:1601–10.
4.
4. Baigent C, Keech A, Kearney PMet al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet2005;366:1267–78.
5.
5. La Rosa JC, He J, Vupputuri S.Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA1999;282:2340–6.
6.
6. Cannon CP, Braunwald E, McCabe CHet al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004;350:1495–504.
7.
7. LaRosa JC, Grundy SM, Waters DDet al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med2005;352:1425–35.
8.
8. Pedersen TR, Faergeman O, Kastelein JJPet al.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA2005;294:2437–45.
10. Jones PH, Davidson MH, Stein EAet al.Comparison of the efficacy and safety of rosuva-statin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol2003;92:152–60.
11.
11. Balk EM, Lau J, Goudas Cet al.Effects of statins on nonlipid serum markers associated with cardiovascular disease. A systematic review. Ann Intern Med2003;139:670–82.
12.
12. Nissen SE, Nicholls SJ, Sipahi Iet al.Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA2006;295:1556–65.
13.
13. Carroll MD, Lacher DA, Sorlie PDet al.Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA2005;294:1773–81.
14.
14. Ford ES, Giles WH, Dietz WH.Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA2002;287:356–9.
15.
15. The Pan-Asian Consensus Panel on HDL-C. Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. Br J Diabetes Vasc Dis2005;5(suppl 2):S1–S16.
16.
16. Waldius G, Jungner I, Holme Iet al.High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet2001;358:2026–33.
17.
17. Yusuf S, Hawken S, Ounpuu Set al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet2004;364:937–52.
18.
18. Walldius G, Aastveit AH, Jungner I.Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med2006;259:259–66.
19.
19. Gordon T, Castelli WP, Hjortland MCet al.High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med1977;62:707–14.
20.
20. Assmann G, Cullen P, Schulte H.Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the PROCAM Study. Circulation2002;105:310–15.
21.
21. Gordon DJ, Probstfield JL, Garrison RJet al.High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation1989;79:8–15.
22.
22. Gordon T, Kannel WB, Castelli WP, Dawber TR.Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med1981;141:1128–31.
23.
23. Koro CE, Bowlin SJ, Stump TEet al.The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J2006;151:755 e1-755.e6.
24.
24. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis1996;121:1–12.
26. Assman G, Nofer J-R. Atheroprotective effects of high density lipoproteins. Ann Rev Med2003;54:321–41.
27.
27. Nofer J-R, Kehrel B, Fobker Met al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis2002;161:1–16.
28.
28. Calabresi L, Gomaraschi M, Franceschini G.Endothelial protection by high density lipoproteins. Arterioscler Thromb Vasc Biol2003;23:1724–31.
29.
29. Von Birgelen C, Hartmann M, Mintz GSet al.Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed by serial long-term (≥ 12 months) follow-up intravascular ultrasound. Circulation2003;108:2757–62.
30.
30. Von Birgelen C, Hartmann M, Mintz GSet alRelationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation2004;110:1579–85.
31.
31. Nissen SE, Tsunoda T, Tuzcu EMet al.Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA2003;290:2292–300.
32.
32. Johnsen SH, Mathiesen EB, Fosse Eet al.Elevated high-density lipoprotein cholesterol levels are protective against plaque progression. A follow-up study of 1952 persons with carotid atherosclerosis. The Tromsø study. Circulation2005;112:498–504.
33.
33. Chapman MJ, Assmann G, Fruchart J-C, Shepherd J, Sirtori Con behalf of the European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin2004;20:1253–68.
34.
34. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360–81.
35.
35. Canner PL, Berge KG, Wenger NKet al.Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol1986;8:1245–55.
36.
36. Rubins HB, Robins SJ, Collins Det al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med1999;341:410–18.
37.
37. Robins SJ, Collins D, Wittes JTet al.Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA2001;285:1585–91.
38.
38. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J.High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin2005;21:1927–34.
39.
39. Wei L, Murphy MJ, MacDonald TM. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. Heart2006;92:746–51.
40.
40. Nissen SE, Tuzcu EM, Schoenhagen Pet al.Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med2005;352:29–38.
41.
41. Carlson LA, Rosenhamer G.Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand1988;223:405–18.
42.
42. Whitney EJ, Krasuski RA, Personius BEet al.A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med2005;142:95–104.
43.
43. Rosenson R.Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J2006;151: 556–63.
44.
44. Sacks FM, Tonkin AM, Shepherd Jet al.The effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation2000;102:1893–900.
45.
45. Brown BG, Zhao XQ, Chait Aet al.Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med2001;345:1583–92.
46.
46. Taylor AJ, Sullenberger LE, Lee HJet al.Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512–17.
47.
47. Greenland P, Abrams J, Aurigemma GPet al.AHA Scientific Statement. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention: non-invasive tests of atherosclerotic burden: Writing Group III. Circulation2000;101:e16–e22.
48.
48. Taylor AJ, Sullenberger LE, Lee HY. ARBITER 3: Atherosclerosis regression during open-label continuation of extended-release niacin following ARBITER 2. Circulation2005;112(17)suppl II:II-179(abstract 943).
49.
49. Moffatt RJ, Chelland SA, Pecott DL, Stamford BAAcute exposure to environmental tobacco smoke reduces HDL-C and HDL2-C. Prev Med2000;38:637–41.
50.
50. Kelley GA, Kelley KS, Tran ZV. Walking, lipids, and lipoproteins: a meta-analysis of randomized controlled trials. Prev Med2004;38:651–61.
51.
51. Rimm EB, Williams P, Fosher Ket al.Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ1999;319:1523–8.
52.
52. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord1997;21(suppl 1):S5–S9.
53.
53. Harper CR, Jacobson TA. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. Am J Cardiol2005;96:1521–9.
54.
54. Belalcazar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis1998;41:151–74.
55.
55. Chapman MJ.Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis2003;171:1–13.
56.
56. Steiner G.Fibrates and coronary risk reduction. Atherosclerosis2005;182:199–207.
57.
57. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol2005;45:185–97.
58.
58. Athyros VG, Papageorgiou A, Athyrou VVet al.Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care2002;25:1198–202.
59.
59. Grundy SM, Vega GL, Yuan Zet al.Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol2005;95:462–8.
60.
60. Durrington PN, Tuomilehto J, Hamann Aet al.Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diabetes Res Clin Pract2004;64:137–51.
61.
61. Wierzbicki AS, Mikhailidis DP, Wray Ret al.Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin2003;19:155–68.
62.
62. Keech A, Simes RJ, Barter Pet al.Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:1849–61.
63.
63. Ellen RL, McPherson R.Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol1998;81:60B–65B.
64.
64. De la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther1999;66:166–72.
65.
65. Colhoun H.After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?Lancet2005;366:1829–31.
66.
66. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Available from www.accordtrial.org, accessed 13 February 2006.
67.
67. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med2005;258:94–114.
68.
68. McCormack PL, Keating GM. Prolonged-release nicotinic acid. A review of its use in the treatment of dyslipidaemia. Drugs2005;65:2719–40.
69.
69. Morgan JM, Capuzzi DM, Guyton JRet al.Treatment effect of NIAS-PAN, a controlled-release nicotinic acid, in patients with hypercholes-terolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther1996;1:195–202.
70.
70. Goldberg A, Alagona P Jr, Capuzzi DMet al. Multiple-dose efficacy and safety of an extended-release form of nicotinic acid in the management of hyperlipidemia. Am J Cardiol2000;85:1100–05.
71.
71. Shepherd J, Betteridge J, Van Gaal Lon behalf of a European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome. A position paper developed by a European Consensus Panel. Curr Med Res Opin2005;21:665–82.
72.
72. Knopp RH, Alagona P, Davidson Met al.Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism1998;47:1097–104.
73.
73. HPS2-THRIVE study. Available from http://www.ctsu.ox.ac.uk/news/hps2_thrive.htm (Accessed 26 June 2006).
74.
74. McGovern ME.Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br J Diabetes Vasc Dis2004;4:78–85.
75.
75. Kashyap ML, McGovern ME, Berra Ket al.Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol2002;89:672–8.
76.
76. Bays HE, Dujovne CA, McGovern MEet al.Comparison of once-daily niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin [the Advicor Versus Other Cholesterol-modulating Agents Trial Evaluation (ADVOCATE)]. Am J Cardiol2003;91:667–72.
77.
77. Capuzzi DM, Morgan JM, Weiss RJet al.Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemiaand low high-density lipoprotein cholesterol levels. Am J Cardiol2003;91:1304–10.
78.
78. Hunninghake DB, McGovern ME, Koren Met al.A dose-ranging study of a new, once daily dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol2003;26:112–18.
79.
79. Insull Jr W, McGovern ME, Schrott Het al.Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med2004;164:1121–17.
80.
80. Clinical Trial: AIM HIGH: Niacin plus statin to prevent vascular events. Available from www.clinicaltrials.gov.ct/show/NCT00120289. Accessed 13 Feb 2006.
81.
81. De Grooth GT, Kuivenhoven JA, Stalenhoef AFHet al.Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. Circulation2002;105:2159–65.
82.
82. Clark RW, Sutfin TA, Ruggeri RBet al.Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein. An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol2004;24:490–7.
83.
83. Brousseau ME, Schaefer EJ, Wolfe MLet al.Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med2004;350:1505–15.
84.
84. Brewer HB.Increasing HDL cholesterol levels. N Engl J Med2004;350:1491–4.
85.
85. De Grooth GJ, Klerkx AH, Stroes ESet al.A review of CETP and its relation to atherosclerosis. J Lipid Res2004;45:1967–74.
86.
86. Tonstad S.Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr Metab Cardiovasc Dis2006;16:156–62.
87.
87. Wierzbicki AS.Lipid-altering drugs: the future. Int J Clin Pract2004;58:1063–72.
88.
88. Chapman MJ.Therapeutic elevation of HDL cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacology and Therapeutics2006;111:893–908.
